We serve (S)-Methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxypropyl)benzoate CAS:142569-69-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: (S)-Methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxypropyl)benzoate
CAS.NO:142569-69-5
Synonyms:
Acid Methyl Ester [R-(E)-2-[3-[3-[2-(7-Chloro-2)
Benzoic acid, 2-[(3S)-3-[3-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxypropyl]-, methyl ester
BENZOIC ACID,2-[3-(S)-[3-(E)-[2-(7-CHLORO-2-QUINOLINYL)ETHENYL]PHENYL]-3-HYDROXY
methyl 2-[3-(S)-[3-[2-(7-chloro-2-quiolinyl)ethenyl]-phenyl]-3-hydroxypropyl]benzoate
Molecular Formula:C28H24ClNO3
Molecular Weight:457.94800
Physical and Chemical Properties:
Density: 1.279 g / cm3
Boiling point: 643.972ºC at 760 mmHg
Melting point: 88-90ºC
Flash point: 343.262ºC
Refractive index: 1.668
Specification:
Appearance: Light yellow to yellow lumpy powder
Purity:≥98%
Heavy metals:≤20ppm
Water(KF):≤5%
Packing:
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Montelukast Sodium CAS:151767-02-1
Intermediates of Montelukast CAS:158966-92-8
Contact us for information like (S)-Methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxypropyl)benzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 2-[3-(S)-[3-[2-(7-chloro-2-quiolinyl)ethenyl]-phenyl]-3-hydroxypropyl]benzoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Acid Methyl Ester [R-(E)-2-[3-[3-[2-(7-Chloro-2) Use and application,methyl 2-[3-(S)-[3-[2-(7-chloro-2-quiolinyl)ethenyl]-phenyl]-3-hydroxypropyl]benzoate technical grade,usp/ep/jp grade.
Related News: This part is mainly anti-tumor drugs, prostate drugs and certain hormone drugs.2-Bromo-6-Methyl-3-Nitropyridine manufacturer Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.4-Chloro-2-fluorotoluene supplier The risk to the general public remains low. And we continue to be confident we are in a good position to respond to this developing situation.”10-Bromo-1-decanol acetate vendor The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.
